Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c01028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Zhijie Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China. Hauptthemen laut MEDLINE: Transcription Factors, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: China Pharmaceutical University, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Selective inhibitors targeting the first bromodomain (BD1) or the second bromodomain (BD2) of the bromodomain and extra terminal domain (BET) proteins have triggered extensive research to produce more specific agents. Herein, we described our efforts to design and synthesize a series of selective BET BD2 inhibitors with novel structures. Among them, compound 45 showed single-digit nanomolar potency against BRD4 BD2 (IC50: 1.6 nM) and a 328-fold selectivity for BRD4 BD2 over BRD4 BD1 (IC50: 524 nM). Besides, 45 possessed potent effects on regulating the differentiation of Th17 cells and reducing the levels of Th17-related cytokines by affecting the activation of STAT3 and NF-κB. Further studies demonstrated that 45 had significant therapeutic efficacy in mouse models of imiquimod (IMQ)-induced psoriasis and dextran sulfate sodium (DSS)-induced inflammatory bowel disease (IBD). This work provides a strong foundation for the development of selective BET BD2 inhibitors and the therapeutic strategy for psoriasis and IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
- School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China.
- School of Medicine and Life Sciences, State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Ch…
ORCID-Profile: Jiapeng Zhu, Qinghua Hu, Yadong Chen
Förderung
- China Pharmaceutical University
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, Z., Yin, L., Xiong, Z., Huang, F., Yang, N., Jiang, F., Li, H., Cui, Y., Ren, J., Cheng, Z., Jia, K., Lu, T., Zhu, J., Hu, Q., & Chen, Y. (2023). Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01028
Vancouver
Wang Z, Yin L, Xiong Z, Huang F, Yang N, Jiang F, et al. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01028
BibTeX
@article{Wang2023,
author = {Wang, Zhijie and Yin, Li and Xiong, Zhenghan and Huang, Fei and Yang, Na and Jiang, Fei and Li, Huili and Cui, Yong and Ren, Jiwei and Cheng, Zitian and Jia, Kun and Lu, Tao and Zhu, Jiapeng and Hu, Qinghua and Chen, Yadong},
title = {Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c01028}
}
EUVIMED